PMID- 19881250
OWN - NLM
STAT- MEDLINE
DCOM- 20100607
LR  - 20221207
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 57
IP  - 2
DP  - 2010
TI  - Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with 
      type 2 diabetes.
PG  - 119-26
AB  - Impaired secretion of glucagon-like peptide 1 (GLP-1) has been suggested to 
      contribute to the deficient incretin effect in patients with type 2 diabetes 
      mellitus (T2DM). Recent studies, however, have not always supported this notion. 
      Since Japanese patients with T2DM usually have severe impairment in the 
      earlyphase of insulin secretion, the measurement of incretin secretions in 
      Japanese T2DM patients would be useful for assessing the association between 
      incretin levels and insulin secretion. We conducted an oral glucose tolerance 
      test (75 g) (OGTT) and meal tolerance test (480 kcal) (MTT) for subjects with 
      normal glucose tolerance (NGT, n=12), subjects with impaired glucose tolerance 
      (IGT, n=7), and T2DM patients (n=21). The tests were carried out over 120-min 
      study periods on separate occasions. Intact GLP-1, GIP, and dipeptidyl peptidase 
      (DPP)-IV were measured by ELISA. T2DM exhibited an impaired early phase of 
      insulin secretion and a reduction in glucagon suppression. There were no 
      significant differences in GLP-1 or GIP levels at each sampling time among NGT, 
      IGT, and T2DM after the ingestions; hence the incremental areas under the curve 
      (IAUC) for the three groups were quite similar. The levels of DPP-IV, a limiting 
      enzyme for the degradation of incretins, were comparable among the three groups. 
      The GLP-1-IAUC was not correlated with IAUCs of insulin, C-peptide, or glucagon 
      determined by the OGTT or the MTT. We concluded that intact GLP-1 levels are 
      comparable between non-diabetics and T2DM, suggesting that impaired insulin 
      secretion in Japanese T2DM is not attributable to defect in GLP-1 secretion.
FAU - Lee, Soushou
AU  - Lee S
AD  - Department of Diabetes, Metabolism, and Endocrinology, Showa University School of 
      Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan.
FAU - Yabe, Daisuke
AU  - Yabe D
FAU - Nohtomi, Kyoko
AU  - Nohtomi K
FAU - Takada, Michiya
AU  - Takada M
FAU - Morita, Ryou
AU  - Morita R
FAU - Seino, Yutaka
AU  - Seino Y
FAU - Hirano, Tsutomu
AU  - Hirano T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091031
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Incretins)
RN  - 0 (Insulin)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Asian People
MH  - Diabetes Mellitus, Type 2/*metabolism
MH  - Dipeptidyl Peptidase 4/metabolism
MH  - Gastric Inhibitory Polypeptide/metabolism
MH  - Glucagon-Like Peptide 1/*metabolism
MH  - Glucose Intolerance/metabolism
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Incretins/*metabolism
MH  - Insulin/metabolism
MH  - Insulin Secretion
MH  - Middle Aged
EDAT- 2009/11/03 06:00
MHDA- 2010/06/09 06:00
CRDT- 2009/11/03 06:00
PHST- 2009/11/03 06:00 [entrez]
PHST- 2009/11/03 06:00 [pubmed]
PHST- 2010/06/09 06:00 [medline]
AID - JST.JSTAGE/endocrj/K09E-269 [pii]
AID - 10.1507/endocrj.k09e-269 [doi]
PST - ppublish
SO  - Endocr J. 2010;57(2):119-26. doi: 10.1507/endocrj.k09e-269. Epub 2009 Oct 31.